News – Page 1168 – Endpoints News

Novartis’s blockbuster CDK 4/6 contender LEE011 gets a VIP countdown at the FDA

9 years ago

VIP Clinton supporter pitched campaign chief Podesta on Canadian price controls for the US

9 years ago

What’s on Sanofi’s M&A list now that Medivation is gone? Catalyst gets an SPA; Adaptimmune partners with Merck

9 years ago

NYC’s top research institutions partner on Step 2 in building a biotech hub

9 years ago

2016's drug pricing headwinds threaten a hurricane of new regulations

9 years ago

After a series of PI3k pileups, Genentech offloads a PhII-ready rival for firesale price

9 years ago

AstraZeneca R&D leader Pangalos warns of a post-Brexit UK research retreat without reimbursement reform

9 years ago

Influential Third Rock Ventures marks a decade of high-profile wins and losses with record $616M Fund IV

9 years ago

Manufacturing woes derail a blockbuster contender from Sanofi/Regeneron. Who's next?

9 years ago

Prominent MIT scientist Susan Lindquist dies of cancer; Election fears damaging biotech stocks?; Promethera adds 10M ...

9 years ago

Another Ramaswamy stunt plays well on Wall Street, Martin Shkreli on shame, and more

9 years ago

On the ropes, Opexa shares blasted by PhIIb multiple sclerosis trial flop

9 years ago

Industry vet Ken Moch jumps to the helm of a small biotech with big dreams for treating Alzheimer’s

9 years ago

That EngMab buyout? Celgene agreed to pay up to $3B for BCMA-targeting drug

9 years ago

FDA flashes red light on Sanofi manufacturing infraction, threatening a looming blockbuster decision

9 years ago

ASCO star, backed by billionaires, goes to Astellas in $1.4 billion buyout

9 years ago

Billionaire Bezos, Arch carry a torch for aging R&D, back $116M mega-round for Unity

9 years ago

FDA slaps a partial hold on one of AstraZeneca's crucial durvalumab programs

9 years ago

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

9 years ago

ProQR shares spike on positive PoC study for lead CF drug

9 years ago

Bruised by a punishing Opdivo failure, Bristol-Myers looks to shake up the business, accelerate R&D

9 years ago

Allergan’s executive team orchestrates a $200M buyout to beef up gastroenterology pipeline

9 years ago

Turning pharma castoffs into an instant fortune, Vivek Ramaswamy’s Myovant bags a $218M IPO

9 years ago

Humana spells out its conditional Exondys 51 coverage policy — strings attached

9 years ago

First page Previous page 1165 1166 116711681169 1170 1171 Next page Last page